Curtin University Homepage
  • Library
  • Help
    • Admin

    espace - Curtin’s institutional repository

    JavaScript is disabled for your browser. Some features of this site may not work without it.
    View Item 
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item
    • espace Home
    • espace
    • Curtin Research Publications
    • View Item

    Drug treatment and cost of cardiovascular disease in Australia

    Access Status
    Open access via publisher
    Authors
    Ademi, Z.
    Liew, D.
    Chew, D.
    Conner, G.
    Shiel, L.
    Nelson, M.
    Soman, A.
    Steg, G.
    Bhatt, D.
    Reid, Christopher
    Date
    2009
    Type
    Journal Article
    
    Metadata
    Show full item record
    Citation
    Ademi, Z. and Liew, D. and Chew, D. and Conner, G. and Shiel, L. and Nelson, M. and Soman, A. et al. 2009. Drug treatment and cost of cardiovascular disease in Australia. Cardiovascular Therapeutics. 27 (3): pp. 164-172.
    Source Title
    Cardiovascular Therapeutics
    DOI
    10.1111/j.1755-5922.2009.00090.x
    ISSN
    1755-5914
    School
    Department of Health Policy and Management
    URI
    http://hdl.handle.net/20.500.11937/2864
    Collection
    • Curtin Research Publications
    Abstract

    Australia's Pharmaceutical Benefits Scheme supports the use of effective drugs for the prevention and control of cardiovascular risk factors. However, there are little data available describing per person costs of medication in primary prevention and secondary prevention in the community. We aim to understand annual expenditure on cardiovascular medicines according to the level and extent of cardiovascular disease, using participants enrolled in the Reduction of Atherothrombosis for Continued Health (REACH) registry. 2873 participants were recruited into the REACH registry through 273 Australian general practices. Cardiovascular medicines review was undertaken at baseline. Average weighted costs of medications were estimated using government-reimbursed prices. Annual costs were stratified by disease extent and location. The annual mean cost of pharmaceuticals per person was AU$1307. The average reported medicine use per person across all states and participants groups varied significantly. Participants with cerebrovascular or peripheral arterial disease were prescribed less cardiovascular medication than those with coronary artery disease (CAD) (mean number of drugs 3.5 vs. 4.5, P < 0.0001) and (3.6 vs. 4.5, P < 0.0001), while those with risk factor alone had the same medication use as those with CAD (mean number 4.5). Medication use was lower in Western Australia in comparison to eastern States. Participants with existing cerebrovascular disease and peripheral vascular disease receive less preventive therapy than those with CAD or even risk factors alone. This observation is consistent across all mainland states. Given the evidence of the effectiveness and cost-effectiveness of treating all types of vascular diseases, the present study suggests that there is scope to improve the treatment of these high-risk participants in Australia. © 2009 Blackwell Publishing Ltd.

    Related items

    Showing items related by title, author, creator and subject.

    • The Effect of a Cardiovascular Polypill Strategy on Pill Burden.
      Truelove, M.; Patel, A.; Bompoint, S.; Brown, A.; Cass, A.; Hillis, G.; Peiris, D.; Rafter, N.; Reid, Christopher; Rodgers, A.; Tonkin, A.; Usherwood, T.; Webster, R.; Kanyini GAP Collaboration (2015)
      AIMS: Recent trials of cardiovascular polypills in high-risk populations show improvements in use of cardiovascular preventive treatments, compared to usual care. We describe patterns of pill burden in Australian practice, ...
    • Cost-effectiveness of low-dose rivaroxaban and aspirin versus aspirin alone in people with peripheral or carotid artery disease: An Australian healthcare perspective
      Zomer, E.; Si, S.; Hird, T.; Liew, D.; Owen, A.; Tonkin, A.; Reid, Christopher; Ademi, Z. (2018)
      Aims: Peripheral artery disease affects 1.2% of the population globally and is associated with an increased risk of atherothrombotic cardiovascular events, major adverse limb events and mortality. The Cardiovascular ...
    • Medication incidents in a private hospital : frequency, type, causes and outcomes
      McKnight, David (2011)
      Background: Medication Safety has become a major health issue in Australia and internationally. Medication use is a part of most people lives with around seven in ten Australians and nine in ten older Australians having ...
    Advanced search

    Browse

    Communities & CollectionsIssue DateAuthorTitleSubjectDocument TypeThis CollectionIssue DateAuthorTitleSubjectDocument Type

    My Account

    Admin

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Follow Curtin

    • 
    • 
    • 
    • 
    • 

    CRICOS Provider Code: 00301JABN: 99 143 842 569TEQSA: PRV12158

    Copyright | Disclaimer | Privacy statement | Accessibility

    Curtin would like to pay respect to the Aboriginal and Torres Strait Islander members of our community by acknowledging the traditional owners of the land on which the Perth campus is located, the Whadjuk people of the Nyungar Nation; and on our Kalgoorlie campus, the Wongutha people of the North-Eastern Goldfields.